|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
CONCURRENT USE MAY INDUCE HYPOKALEMIA AND MAY POTENTIATE DIGITALIS TOXICITY
|
CO-ADMINISTRATION OF DIGOXIN WITH ALPRAZOLAM RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR IN VOLUME OF DISTRIBUTION OF THE DRUG WITH IMPLICATION THAT DIGITALIS TOXICITY MAY RESULT
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
ANTACIDS MAY INTERFERE WITH INTESTINAL DIGOXIN ABSORPTION RESULTING IN UNEXPECTEDLY LOW SERUM CONCENTRATIONS
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|